Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2023 Sep 18

PMID 37719086

Authors

Qianqian Wang

Chunxaing Feng

Yuchun Chen

Tianming Peng

Yong Li

Kunlin Wu

Xiaoyong Pu

Hanzhong Chen

Jiumin Liu

Affiliations

Soon will be listed here.

Abstract

Background: CD47 has high levels of expression in malignant cancer cells, which binds to SIRP- to release the "don't eat me" signal and prevents mononuclear macrophages from phagocytosing the cells. Resistance to drugs and metastases are potential barriers for prostate cancer endocrine therapy. Although immunotherapy for tumors has developed rapidly in the last few decades, its effectiveness in treating prostate cancer is unsatisfactory. Prostate cancer has a high-expression level of CD47. Therefore, a novel approach for potential immunotherapy may be provided by investigating the relationship among CD47 and the infiltration of immune cells in the prostate carcinoma.

Methods: The GEPIA database was utilized to compare the abundance of CD47 in malignant tissues with tissues that were normal. Furthermore, the function of CD47 in prostate carcinoma was assessed by CancerSEA. The association among CD47 and the tumor microenvironment was assessed utilizing the TISCH single cell data database. By using TIMER, the connection among CD47 and immunological invasion of prostate cancer was explored. Moreover, macrophages were cocultured with mouse prostate cancer cell RM-1 blocked by CD47 antibody to observe the changes in phagocytosis efficiency .

Results: Expression level of CD47 is upregulated in prostate carcinoma, and it is closely connected with prostate cancer's inadequate immune invasion. CD47 antibody blocking promotes macrophage phagocytosis of RM-1.

Conclusion: Our research demonstrates a closely relationship among CD47 and the immunological microenvironment of prostate cancer, and blocking CD47 can promote macrophages to phagocytosis of prostate cancer cells. Therefore, CD47 may provide novel strategies for potential immunotherapy of prostate cancer.

References

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Tien F, Lu H, Lin S, Tsai H . Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities. J Biomed Sci. 2023; 30(1):3. PMC: 9832644. DOI: 10.1186/s12929-022-00893-0. View

Yuan H, Yan M, Zhang G, Liu W, Deng C, Liao G . CancerSEA: a cancer single-cell state atlas. Nucleic Acids Res. 2018; 47(D1):D900-D908. PMC: 6324047. DOI: 10.1093/nar/gky939. View

Burger P, Hilarius-Stokman P, de Korte D, van den Berg T, van Bruggen R . CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood. 2012; 119(23):5512-21. DOI: 10.1182/blood-2011-10-386805. View

Sadasivan S, Chen Y, Gupta N, Han X, Bobbitt K, Chitale D . The interplay of growth differentiation factor 15 (GDF15) expression and M2 macrophages during prostate carcinogenesis. Carcinogenesis. 2020; 41(8):1074-1082. PMC: 7422623. DOI: 10.1093/carcin/bgaa065. View

Li S, Yu J, Huber A, Kryczek I, Wang Z, Jiang L . Metabolism drives macrophage heterogeneity in the tumor microenvironment. Cell Rep. 2022; 39(1):110609. PMC: 9052943. DOI: 10.1016/j.celrep.2022.110609. View

Ntala C, Salji M, Salmond J, Officer L, Teodosio A, Blomme A . Analysis of Prostate Cancer Tumor Microenvironment Identifies Reduced Stromal CD4 Effector T-cell Infiltration in Tumors with Pelvic Nodal Metastasis. Eur Urol Open Sci. 2021; 29:19-29. PMC: 8317840. DOI: 10.1016/j.euros.2021.05.001. View

Brown E, Frazier W . Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001; 11(3):130-5. DOI: 10.1016/s0962-8924(00)01906-1. View

Anderson K, Stromnes I, Greenberg P . Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell. 2017; 31(3):311-325. PMC: 5423788. DOI: 10.1016/j.ccell.2017.02.008. View

10.

Mantovani A, Allavena P, Marchesi F, Garlanda C . Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022; 21(11):799-820. PMC: 9380983. DOI: 10.1038/s41573-022-00520-5. View

11.

Pittet M, Michielin O, Migliorini D . Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022; 19(6):402-421. DOI: 10.1038/s41571-022-00620-6. View

12.

Cossarizza A, Chang H, Radbruch A, Abrignani S, Addo R, Akdis M . Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). Eur J Immunol. 2021; 51(12):2708-3145. PMC: 11115438. DOI: 10.1002/eji.202170126. View

13.

Chen Q, Wang C, Zhang X, Chen G, Hu Q, Li H . In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2018; 14(1):89-97. DOI: 10.1038/s41565-018-0319-4. View

14.

Chen S, Zhu G, Yang Y, Wang F, Xiao Y, Zhang N . Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat Cell Biol. 2021; 23(1):87-98. DOI: 10.1038/s41556-020-00613-6. View

15.

He H, Liang L, Han D, Xu F, Lyu J . Different Trends in the Incidence and Mortality Rates of Prostate Cancer Between China and the USA: A Joinpoint and Age-Period-Cohort Analysis. Front Med (Lausanne). 2022; 9:824464. PMC: 8850968. DOI: 10.3389/fmed.2022.824464. View

16.

Komori S, Saito Y, Nishimura T, Respatika D, Endoh H, Yoshida H . CD47 promotes peripheral T cell survival by preventing dendritic cell-mediated T cell necroptosis. Proc Natl Acad Sci U S A. 2023; 120(33):e2304943120. PMC: 10440595. DOI: 10.1073/pnas.2304943120. View

17.

Wu Z, Chen H, Luo W, Zhang H, Li G, Zeng F . The Landscape of Immune Cells Infiltrating in Prostate Cancer. Front Oncol. 2020; 10:517637. PMC: 7658630. DOI: 10.3389/fonc.2020.517637. View

18.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

19.

Zhong W, Shen Z, Wu Y, Mao X, Kong J, Wu W . Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study. Front Immunol. 2022; 13:1014981. PMC: 9647028. DOI: 10.3389/fimmu.2022.1014981. View

20.

Mukherjee A, Wanjari U, Prabakaran D, Ganesan R, Renu K, Dey A . The Cellular and Molecular Immunotherapy in Prostate Cancer. Vaccines (Basel). 2022; 10(8). PMC: 9416492. DOI: 10.3390/vaccines10081370. View